Can the use of the Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonist rosiglitazone reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndrome?
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms ROSI-TRIAL
- 02 Mar 2007 New trial record.